Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer

Pharmaceutical Research

Volumn 29, Issue 8, 2012, Pages 2079-2091

  Danquah, Michael ^a   Duke III, Charles B ^a   Patil, Renukadevi ^a   Miller, Duane D ^a   Mahato, Ram I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Androgen receptor; Antiandrogen; Bicalutamide; Embelin; Polymeric micelles; Prostate cancer; XIAP

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CBDIV 17; COPOLYMER; EMBELIN; EMBELIN 6G; MACROGOL; N [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 3 [(4 CYANOPHENYL)(METHYL)AMINO] 2 HYDROXY 2 METHYLPROPANAMIDE; POLYETHYLENE GLYCOL B POLY(CARBONATE CO LACTIDE) COPOLYMER; SERINE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN C4 2; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; HYDROPHOBICITY; IC 50; IN VIVO STUDY; MALE; MICELLE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYBUTYRATES; MALE; MICE; MICELLES; NITRILES; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84864491719     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0737-1     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991;324:236-45.
3. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am. 1991;18:15-24.
4. Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, et al. Cancer of the prostate. Crit Rev Oncol Hematol. 2005;56:379-96.
5. Goktasand S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999;26:162-73.
6. Danquah M, Li F, Duke 3rd CB, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res. 2009;26:2081-92.
7. Scherand HI, Sawyers CL. Biology of progressive, castrationresistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23: 8253-61.
8. Taplinand ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004;91:483-90.
9. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63:623-39.
10. Danquah M, Fujiwara T, Mahato RI. Self-assembling methoxypoly (ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials. 2010;31:2358-70.
11. Li F, Danquah M, Mahato RI. Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules. 2010;11:2610-20.
12. Li F, Danquah M, Singh S, Wu H, Mahato RI. Paclitaxel- and lapatinib-loaded lipopolymer micelles overcomemultidrug resistance in prostate cancer. Drug Deliv Transl Res. 2011;1:240-8.
13. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, et al. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene. 2006;25:3905-13.
14. Wu Y, Chhipa RR, Zhang H, Ip C. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther. 2011;11:902-9.
15. Chen J, Nikolovska-Coleska Z, Wang G, Qiu S, Wang S. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg Med Chem Lett. 2006;16:5805-8.
16. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr. 1995;5:97-125.
17. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998;273:7787-90.
18. Fesik SW. Insights into programmed cell death through structural biology. Cell. 2000;103:273-82.
19. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104:791-800.
20. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES, et al. Structural basis of caspase-7 inhibition by XIAP. Cell. 2001;104:769-80.
21. Liu S, Yuan Y, Okumura Y, Shinkai N, Yamauchi H. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Biochem Biophys Res Commun. 2010;394:297-302.
22. Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene. 2000;19:1924-32.
23. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005;4:1311-9.
24. Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, et al. First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorg Med Chem. 2007;15:3413-21.
25. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination withTRAIL and Bortezomib. Br J Cancer. 2010;102:1707-16.
26. Huerta S, Gao X, Livingston EH, Kapur P, Sun H, Anthony T. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery. 2010;148:346-53.
27. Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, et al. Overview of Taxol safety. J Natl Cancer Inst Monogr. 1993;131-9.
28. Dai Y, Desano J, Qu Y, Tang W, Meng Y, Lawrence TS, et al. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am J Cancer Res. 2011;1:128-43.